
Rondo Therapeutics: Developing novel bispecific antibodies to combat cancer, since 2021.
Rondo Therapeutics, founded in 2021 and headquartered in Hayward, California, focuses on developing novel bispecific antibodies to combat cancer. The company's core mission is to harness the immune system to safely target and eliminate tumors, specifically solid tumors, while maximizing efficacy and minimizing side effects. Rondo Therapeutics aims to revolutionize cancer treatment through its innovative approach to immune-cell engaging bispecific antibodies.
The company is supported by top investors and guided by a dynamic team of seasoned entrepreneurs, exceptional scientists, and industry-leading advisors. Rondo Therapeutics has made significant strides in its pipeline development, positioning itself as a promising player in the oncology sector. Its impact lies in its potential to offer more effective and safer cancer therapies, contributing to the advancement of immuno-oncology.

Immune-Onc Therapeutics
immuneonc.com

Soteria Biotherapeutics

Crossbow Therapeutics
crossbowtx.com

Trio Pharmaceuticals

A2 Biotherapeutics
a2bio.com

Valink Therapeutics
valinktx.com

Solve Therapeutics

OncoResponse

Marengo Therapeutics
marengotx.com

Dren Bio
drenbio.com

RevOpsis Therapeutics
revopsis.com

GO Therapeutics
gotherapeutics.com

SunnyBay BioTech

Angarus Therapeutics
angarustx.com

LiliumX
liliumx.com
Companies similar to Rondo Therapeutics include Immune-Onc Therapeutics, Soteria Biotherapeutics, Crossbow Therapeutics and Trio Pharmaceuticals.
Rondo Therapeutics was founded in 2019.
Rondo Therapeutics' headquarters is located in Hayward, CA, US.
Rondo Therapeutics' most recent funding round was for $67M (USD) in March 2022.
As of Mar 2, 2022, Rondo Therapeutics has raised a total of $67M (USD).
Rondo Therapeutics has 12 employees as of Feb 4, 2024.